This presentation discusses quality of life after CAR T-cell therapy, potential short-term, late, and long-term side effects, incidence and risk factors for late and long-term side effects, how to monitor yourself for side effects, when and to whom you should report symptoms, and lifestyle changes that can help prevent or manage long-term effects of CAR T-cell therapy.

Transcription: 00:03 (Marla): Welcome to the workshop, The Present and Future of CAR T-Cell Therapy. My name is Marla, and I will be your moderator for this workshop. Before we

This session features leading experts in CAR T-cell therapy for lymphoma and multiple myeloma, and a social worker who helps CAR T patients manage psychosocial and financial challenges during and after treatment. They discuss current CAR T therapies available for myeloma and lymphoma patients, side effects and outcomes after CAR T-cell therapy, and new CAR T products on the horizon.

This presentation gives a thorough description of the CAR T-cell therapy process for B-cell acute lymphoblastic leukemia (B-cell ALL), and discusses short- and long-term side effects and toxicities, expected outcomes, and ongoing research related to this therapy.

This presentation discusses CAR T-cell therapy for multiple myeloma. It explains what CAR T-cell therapy is, the process, and what clinical trials are indicating in regards to short- and long-term side effects, patient outcomes, and quality of life.

CAR T cell therapy has become an increasingly common treatment for patients with diffuse large B-cell lymphoma, (DLBCL), follicular lymphoma (FL), and mantle cell lymphoma. This presentation discusses how it works, who is a good candidates for CAR T-cell therapy, and the risks and benefits of the treatment.

CAR T-cell therapy is a type of specialized immunotherapy that uses the patient's own modified T-cells to fight cancer. It is approved to treat certain blood cancers like lymphoma, leukemia, and multiple myeloma.

La terapia de células CAR T es un tratamiento nuevo para pacientes que tienen ciertos tipos de linfoma no Hodgkin. Conozca lo que implica someterse a una terapia de células CAR T, quién es un buen candidato y los posibles resultados.

Multiple studies have shown that most patients who receive chimeric antigen receptor (CAR) T-cell therapy report a good quality of life long-term. Learn how CAR T-cell therapy is performed and its short-term and long-term effects on patients and caregivers. Discover key differences between CAR T-cell, stem cell transplant and other and chemotherapy treatments.

Advanced age has traditionally been seen as prohibitive for treatments like stem cell transplants and CAR T therapy. This presentation reviews evidence that overall fitness is a crucial factor in reducing non-relapse mortality and that otherwise healthy elderly patients can have successful outcomes after transplant and CAR T-cell therapy.